In combination, atezolizumab used in addition to a VEGF inhibitor plus chemotherapy significantly improved overall survival as well as progression-free survival in patients with metastatic NSCLC (Socinski et al., 2018). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.